Literature DB >> 31123140

CSF chitinase proteins in amyotrophic lateral sclerosis.

Alexander G Thompson1, Elizabeth Gray1, Alexander Bampton1, Dominika Raciborska2, Kevin Talbot1, Martin R Turner3.   

Abstract

OBJECTIVE: To evaluate the classifier performance, clinical and biochemical correlations of cerebrospinal fluid (CSF) levels of the chitinase proteins Chitotriosidase-1 (CHIT1), Chitinase-3-like protein 1 (CHI3L1) and Chitinase-3-like protein 2 (CHI3L2) in amyotrophic lateral sclerosis (ALS).
METHODS: CSF levels of CHIT1, CHI3L1, CHI3L2, phosphorylated neurofilament heavy chain (pNFH) and C-reactive protein were measured by ELISA in a longitudinal cohort of patients with ALS (n=82), primary lateral sclerosis (PLS, n=10), ALS-mimic conditions (n=12), healthy controls (n=25) and asymptomatic carriers of ALS-causing genetic mutations (AGC; n=5).
RESULTS: CSF CHIT1, CHI3L1 and CHI3L2 were elevated in patients with ALS compared with healthy controls (p<0.001) and ALS-mimics (CHIT1, p<0.001; CHI3L1, p=0.017; CHI3L2, p<0.001). CHIT1 and CHI3L2 were elevated in ALS compared with PLS (CHIT1, p=0.021; CHI3L1, p=0.417; CHI3L2, p<0.001). Chitinase levels were similar in AGCs and healthy controls. Chitinase proteins distinguished ALS from healthy controls (area under the curve (AUC): CHIT1 0.92; CHI3L1 0.80; CHI3L2 0.90), mimics (AUC: CHIT1 0.84; CHI3L1 0.73; CHI3L2 0.88) and, to a lesser extent, PLS (AUC: CHIT 0.73; CHI3L1 0.51; CHI3L2 0.82) but did not outperform pNFH. CHIT1 and CHI3L2 correlated with disease progression rate (Pearson's r=0.49, p<0.001; r=0.42, p<0.001, respectively). CHI3L1 correlated with degree of cognitive dysfunction (r=-0.25, p=0.038). All chitinases correlated with pNFH. CHIT1 levels were associated with survival in multivariate models. Chitinase levels were longitudinally stable.
CONCLUSIONS: CSF chitinase proteins may have limited value as independent diagnostic and stratification biomarkers in ALS, but offer a window into non-autonomous mechanisms of motor neuronal loss in ALS, specifically in assessing response to therapies targeting neuroinflammatory pathways. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  amyotrophic lateral sclerosis; biomarker; inflammation; microglia; motor neuron disease

Mesh:

Substances:

Year:  2019        PMID: 31123140     DOI: 10.1136/jnnp-2019-320442

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

1.  Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.

Authors:  Samir Abu-Rumeileh; Veria Vacchiano; Corrado Zenesini; Barbara Polischi; Silvia de Pasqua; Enrico Fileccia; Angela Mammana; Vitantonio Di Stasi; Sabina Capellari; Fabrizio Salvi; Rocco Liguori; Piero Parchi
Journal:  J Neurol       Date:  2020-02-25       Impact factor: 4.849

Review 2.  The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?

Authors:  Rangariroyashe H Chipika; We Fong Siah; Mary Clare McKenna; Stacey Li Hi Shing; Orla Hardiman; Peter Bede
Journal:  J Neurol       Date:  2020-10-31       Impact factor: 6.682

3.  Metabolite Profiling Reveals Predictive Biomarkers and the Absence of β-Methyl Amino-l-alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis.

Authors:  Michael S Bereman; Kaylie I Kirkwood; Tharani Sabaretnam; Sarah Furlong; Dominic B Rowe; Gilles J Guillemin; Allyson L Mellinger; David C Muddiman
Journal:  J Proteome Res       Date:  2020-06-02       Impact factor: 4.466

Review 4.  Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers.

Authors:  Björn F Vahsen; Elizabeth Gray; Alexander G Thompson; Olaf Ansorge; Daniel C Anthony; Sally A Cowley; Kevin Talbot; Martin R Turner
Journal:  Nat Rev Neurol       Date:  2021-04-29       Impact factor: 42.937

Review 5.  Cognitive dysfunction in amyotrophic lateral sclerosis: can we predict it?

Authors:  Fabiola De Marchi; Claudia Carrarini; Antonio De Martino; Luca Diamanti; Antonio Fasano; Antonino Lupica; Mirella Russo; Simone Salemme; Edoardo Gioele Spinelli; Alessandro Bombaci
Journal:  Neurol Sci       Date:  2021-03-27       Impact factor: 3.307

6.  Monocyte-Derived Macrophages Contribute to Chitinase Dysregulation in Amyotrophic Lateral Sclerosis: A Pilot Study.

Authors:  Nayana Gaur; Elena Huss; Tino Prell; Robert Steinbach; Joel Guerra; Akash Srivastava; Otto W Witte; Julian Grosskreutz
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

7.  CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis.

Authors:  Elizabeth Gray; Alexander G Thompson; Joanne Wuu; Joe Pelt; Kevin Talbot; Michael Benatar; Martin R Turner
Journal:  Ann Clin Transl Neurol       Date:  2020-07-14       Impact factor: 4.511

Review 8.  Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia.

Authors:  Timothy Fullam; Jeffrey Statland
Journal:  Brain Sci       Date:  2021-05-11

Review 9.  Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Authors:  Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini
Journal:  Neurosci Biobehav Rev       Date:  2021-06-19       Impact factor: 9.052

Review 10.  The Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis: Signals From the CNS and Beyond.

Authors:  Nayana Gaur; Caroline Perner; Otto W Witte; Julian Grosskreutz
Journal:  Front Neurol       Date:  2020-05-27       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.